In another Phase 3 trial of eprenetapopt and azacitidine as a frontline regimen in TP53 mutant MDS (NCT03745716), the study failed to meet its primary endpoint, underscoring again the limited therapeutic efficacy of pharmacologic p53 reactivation in this high-risk molecular subset [106]. The gene discussed is TP53; the disease is myelodysplastic syndrome.